MedDay is a biotechnology company that develops new drugs for neurological and psychiatric diseases.
MedDay is an international pioneering biopharmaceutical company developing new drugs targeting brain metabolism to treat diseases of the nervous system in areas of high unmet need.
MedDay was founded in 2011 and is based in Paris, France.
MedDay is committed to treating nervous system disorders in areas of high unmet medical need. As well as dedicated to bringing safe and effective drugs to people who need them most.
MedDay provides MD1003, a solution for the treatment of primary and secondary progressive multiple sclerosis; MD1103, a solution for autism spectrum disorders; and MD1105, a solution for Alzheimer’s disease.
MedDay is backed by leading investors such as Andera Partners, Sofinnova Partners, Bpifrance, & InnoBio.